CTMXNasdaqPharmaceutical PreparationsFiscal year ends December 31
CytomX Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$2.34+0.06 (+2.63%)
Close on Oct 19, 2026
- Market cap
- $512.32M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2012 to 2025
Operating margin
-29.3%+88.4 pts over 5 years
Net margin
-22.8%+71.9 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -44.8% | +12.8% | +2.2% | +25.7% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -57.6% | -732.6% | -35.2% | |
| Return on assets | -29.7% | -18.5% | -12.8% | |
| Current ratio | 5.26 | 4.76 | 3.09 | |
| Capex to revenue | 14.5% | 3.4% | 0.3% | |
| Diluted shares | 36M | 46M | 138M |
Where the cash went
Fiscal 2021 to 2025, five years combined
CytomX Therapeutics generated $447.67M from operations and spent $4.72M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$447.67M
Used
$4.72M
Capital expenditure$4.72M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-22.8%
×Asset turnover0.56×
×Equity multiplier2.76×
=Return on equity, FY2025-35.2%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -22.8% | 0.56× | 2.76× | -35.2% |
| FY2024 | 23.1% | 0.86× | -6.73× | -133.1% |
| FY2023 | -0.6% | 0.44× | -3.47× | 0.9% |
| FY2022 | -186.8% | 0.18× | -6.96× | 230.4% |
| FY2021 | -310.5% | 0.11× | -84.79× | 2814.8% |
| FY2020 | -94.7% | 0.20× | 39.55× | -732.6% |
| FY2019 | -493.7% | 0.07× | 4.95× | -164.7% |
| FY2018 | -142.2% | 0.14× | 4.15× | -82.3% |
| FY2017 | -60.2% | 0.24× | 4.02× | -58.1% |
| FY2016 | -391.5% | 0.08× | 1.94× | -57.6% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
1of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$17.37M
- Cash generatingOperating cash flow above zero-$75.59M
- Return on assets improvedROA up on the prior year15.8% → -14.4%
- Earnings backed by cashOperating cash flow above net income-$75.59M vs -$17.37M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose1.25 → 3.09
- No dilutionShare count did not rise85M → 138M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.68 → 0.63